IQ-AI Limited Orphan Drug Designation for GaM in Pediatric GBM (8411F)

TIDMIQAI

RNS Number : 8411F

IQ-AI Limited

13 July 2023

13 July 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

Orphan Drug Designation for GaM in Pediatric GBM

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of pediatric glioblastoma multiforme (GBM).

In February, IB was granted Orphan Drug Designation for adult GBM. The US FDA has since confirmed that the designation granted in February applies to all GBM patients. GBM is the most common and aggressive primary brain tumor in adults and children. There are currently no effective treatments for pediatric glioblastoma.

Oral GaM recently demonstrated significant survival benefits in a pre-clinical study for pediatric GBM. These promising results, coupled with the easy administration by capsule, make this a very attractive potential treatment option for both pediatric and adult patients.

"We are very pleased that the FDA has now confirmed that the orphan drug designation for GaM applies to all GBM populations including pediatric patients," said Trevor Brown, CEO of IQ-AI.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

 
 IQ-AI Ltd 
  Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda 
  Tel: [phone] 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: [phone] 
 

About Imaging Biometrics(R) LLC: IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the

company's website at www.imagingbiometrics.com .   Follow IB on Twitter, @IQAI_IB. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDUUOVROAUBAAR

(END) Dow Jones Newswires

July 13, 2023 02:00 ET (06:00 GMT)